MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

No special precautions for storage. However, complex administration regime makes it unsuitable for MCA.

Stability Notes

Store in well-closed containers.

Provenance

This compatibility recommendation is derived from Actos 15mg tablets (Neon Healthcare Ltd).

Stability Notes

Store in well-closed containers.

Provenance

This compatibility recommendation is derived from Actos 15mg tablets (Neon Healthcare Ltd).

Stability Notes

Store in well-closed containers.

Provenance

This compatibility recommendation is derived from Actos 15mg tablets (Neon Healthcare Ltd).

Stability Notes

Store in well-closed containers.

Provenance

This compatibility recommendation is derived from Actos 30mg tablets (Neon Healthcare Ltd).

Stability Notes

Store in well-closed containers.

Provenance

This compatibility recommendation is derived from Actos 30mg tablets (Neon Healthcare Ltd).

Stability Notes

Store in well-closed containers.

Provenance

This compatibility recommendation is derived from Actos 30mg tablets (Neon Healthcare Ltd).

Stability Notes

Store in well-closed containers.

Provenance

This compatibility recommendation is derived from Actos 45mg tablets (Neon Healthcare Ltd).

Stability Notes

Store in well-closed containers.

Provenance

This compatibility recommendation is derived from Actos 45mg tablets (Neon Healthcare Ltd).

Stability Notes

There are no stability notes available for this medicine.

Stability Notes

There are no stability notes available for this medicine.

Stability Notes

There are no stability notes available for this medicine.

Stability Notes

There are no stability notes available for this medicine.
Print this list

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
Medicines under this category are not suitable for use in MCAs.
These medicines have not been reviewed by SPS.